NVCR - NovoCure Limited

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
46.20
+2.09 (+4.74%)
At close: 4:00PM EDT

46.20 0.00 (0.00%)
Pre-Market: 8:28AM EDT

Stock chart is not supported by your current browser
Previous Close44.11
Open44.49
Bid46.20 x 2200
Ask46.64 x 800
Day's Range44.29 - 46.46
52 Week Range16.90 - 53.70
Volume663,935
Avg. Volume772,196
Market Cap4.274B
Beta (3Y Monthly)3.29
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Why Novocure Stock Jumped 16.3% in September
    Motley Fool6 days ago

    Why Novocure Stock Jumped 16.3% in September

    Shares of this medical device company that's aiming to revolutionize cancer treatment are up 123% in 2018.

  • 3 Medical Devices Stocks to Buy
    InvestorPlace15 days ago

    3 Medical Devices Stocks to Buy

    When you think of medical devices stocks, you don’t think of cloud-connected watches. You want to invest in more prosaic companies, large and small, which offer discrete devices for specific conditions, with Food and Drug Administration (FDA) approvals and positive clinical trials. The long-term prognosis for medical devices is good, but many companies need to deal with short-term problems to get there, so look for strength – financial strength or strength within a winning niche – when you shop for investments.

  • What Investors Should Know About NovoCure Limited’s (NASDAQ:NVCR) Financial Strength
    Simply Wall St.last month

    What Investors Should Know About NovoCure Limited’s (NASDAQ:NVCR) Financial Strength

    Small-caps and large-caps are wildly popular among investors; however, mid-cap stocks, such as NovoCure Limited (NASDAQ:NVCR) with a market-capitalization of US$4.36b, rarely draw their attention. However, history shows that overlookedRead More...

  • 5 Medical Device Stocks With Impressive Staying Power
    InvestorPlacelast month

    5 Medical Device Stocks With Impressive Staying Power

    Easily the biggest trend in investing has to be healthcare stocks. From rising and aging populations in the developed world to new middle-class consumers gaining access to healthcare for the first time in emerging markets, healthcare demand is only getting bigger by the day. All in all, the combination of the two factors makes the medical device stocks some of best plays in all of healthcare.

  • Why Novocure Gained 33% in August
    Motley Foollast month

    Why Novocure Gained 33% in August

    Wall Street is excited about the growing potential for the company's cancer-fighting treatments.

  • NovoCure Stock Rose after Positive Results from Clinical Trial
    Market Realistlast month

    NovoCure Stock Rose after Positive Results from Clinical Trial

    On September 6, NovoCure (NVCR) stock rose 5.3% to reach $45.40 compared to the previous day’s close of $43.10. Also, on September 6, NovoCure hit its 52-week high of $46.73. Its closing price for the day represents ~182% growth from its 52-week low of $16.10 on October 13, 2017.

  • Stocks - Cloudera, Verint Systems, Novocure Soar in Pre-market; Lands' End Tumbles
    Investing.comlast month

    Stocks - Cloudera, Verint Systems, Novocure Soar in Pre-market; Lands' End Tumbles

    Investing.com - Stocks in focus in pre-market trade Thursday:

  • This brain cancer drug stock has been on a tear
    Yahoo Finance2 months ago

    This brain cancer drug stock has been on a tear

    This year, more than 14,000 people in the U.S. will be diagnosed with the same kind of brain cancer that killed Senator John McCain, glioblastoma multiforme, or GBM. 

  • Motley Fool2 months ago

    3 Small-Cap Healthcare Stocks for Your Watch List

    These hidden gems found a niche for themselves and rocked it, and they’re just getting started.

  • What Does NovoCure’s Valuation Trend Indicate?
    Market Realist2 months ago

    What Does NovoCure’s Valuation Trend Indicate?

    NovoCure’s (NVCR) net financial expenses increased from $2.18 million in the second quarter of 2017 to $2.86 million in the second quarter. NovoCure’s income tax expenses also increased from $3.46 million in the second quarter of 2017 to $5.56 million in the second quarter.

  • NovoCure Stock: Key Factors Driving Investors’ Interest
    Market Realist2 months ago

    NovoCure Stock: Key Factors Driving Investors’ Interest

    NovoCure (NVCR) is mainly engaged in developing and bringing tumor treating fields for solid tumors to the market. The company’s first tumor treating fields delivery system, Optune, is targeted to treat adult patients with glioblastoma. Tumor treating fields use electric fields tuned to certain frequencies to disrupt solid tumor cancer cell division.

  • NovoCure’s Top Line Registered Strong Growth
    Market Realist2 months ago

    NovoCure’s Top Line Registered Strong Growth

    NovoCure (NVCR) generated revenues of $61.51 million in the second quarter—compared to $38.38 million in the second quarter of 2017. The growth was also driven by NovoCure’s initial launch efforts in Japan. NovoCure incurred a cost of revenues of $19.83 million in the second quarter—compared to $13.15 million in the second quarter of 2017.

  • Benzinga2 months ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Canopy Growth Corp (NYSE: CGC ) stock gained more ...

  • Forget Bitcoin: You're Better Off Buying These 3 Stocks
    Motley Fool2 months ago

    Forget Bitcoin: You're Better Off Buying These 3 Stocks

    Cryptocurrencies might grab all of the headlines, but these three businesses are better bets for the long term.

  • NovoCure’s Revenues Rose 60% in the Second Quarter
    Market Realist3 months ago

    NovoCure’s Revenues Rose 60% in the Second Quarter

    NovoCure (NVCR) released its second-quarter results on July 26. In the second quarter, NovoCure continued to see steady growth in patient prescriptions for new glioblastoma diagnosis. NovoCure reported a net loss of $15.51 million in the second quarter—compared to a net loss of $21.17 million in the second quarter of 2017.

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of NVCR earnings conference call or presentation 26-Jul-18 12:00pm GMT

    Q2 2018 Novocure Ltd Earnings Call

  • Why Most Analysts Are Bullish on NovoCure
    Market Realist3 months ago

    Why Most Analysts Are Bullish on NovoCure

    NovoCure (NVCR) is expected to incur SG&A (selling, general, and administrative) expenses of $35.4 million in the second quarter, compared with $31.38 million in the second quarter of 2017, an increase of 12.8%. NovoCure’s R&D (research and development) expenses are expected to increase 47.06% from $9.37 million in the second quarter of 2017 to $13.78 million in the second quarter. NovoCure’s total operating expenses are expected to increase 18.1% from $40.75 million in the second quarter of 2017 to $48.13 million in the second quarter.

  • What to Expect from NovoCure’s Q2 2018 Earnings
    Market Realist3 months ago

    What to Expect from NovoCure’s Q2 2018 Earnings

    NovoCure (NVCR) is expected to report its second-quarter earnings on July 26. In this series, we’ll look at the company’s top-line, operational, and bottom-line performance expected by analysts for the second quarter. We’ll also look at analysts’ recommendations and the performance of NovoCure stock so far this year.

  • Market Realist3 months ago

    NASDAQ All-Stars

    Batting first and playing RF, we have GDS Holdings Ltd. (NASDAQ: GDS). GDS is one of the leading carrier-neutral data center solutions providers in China, and the growing demand for its services has led to impressive growth.

  • NovoCure (NVCR) Catches Eye: Stock Jumps 7.4%
    Zacks3 months ago

    NovoCure (NVCR) Catches Eye: Stock Jumps 7.4%

    NovoCure (NVCR) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

  • Here's Why Novocure Ltd. Rose 55% in the First Half of 2018
    Motley Fool3 months ago

    Here's Why Novocure Ltd. Rose 55% in the First Half of 2018

    Fighting cancer with electric fields could be a huge business.

  • InvestorPlace3 months ago

    Trade of the Day: Novocure Ltd (NVCR)

    To receive further updates on this Novocure Ltd (NASDAQ:NVCR) trade as well as an alert when it’s time to take profits, sign up for a risk-free trial of Power Options Weekly today.

  • TheStreet.com4 months ago

    NovoCure's Charts Look Bullish

    NovoCure Limited made a small base pattern in 2016 and started a strong rally in 2017 and moving up four-fold from its 2017 nadir. Let's review the charts and indicators of NVCR to see what the prospects look like for this company.

  • CNBC4 months ago

    Cramer's lightning round: The pecking order for my favorite cybersecurity stocks

    Jim Cramer zooms through his take on callers' favorite stocks and lists his top picks in the cybersecurity space.

  • The Probable Reason Behind NovoCure's Double-Digit Drop Today
    Motley Fool4 months ago

    The Probable Reason Behind NovoCure's Double-Digit Drop Today

    Shares retreat after the company releases details about an upcoming phase 3 trial. Should investors be worried, or is this just market noise?